Skip to main content
. 2022 Nov 17;10:167. doi: 10.1186/s40478-022-01466-w

Table 3.

ATRX status prediction using presence and absence of TP53 and IDH mutations compared to ARTX immunohistochemistry and the FoundationOne targeted next-generation sequencing panel

Infiltrating glioma subgroup Prediction compared to IHC Prediction compared to foundation medicine
Oligodendroglioma 13/13 (100%) 3/3 (100%)
IDH-mutant Infiltrating Astrocytoma 12/22 (55%) 9/12–12/12 (75–100%)
IDH-wild type Infiltrating Astrocytoma, presenting in adults 102/102 (100%) 57/63 – 60/63 (91- 95%)